Hikma Pharmaceuticals Plc (LON:HIK) has been given a consensus recommendation of “Buy” by the ten ratings firms that are currently covering the company. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 2,544.88 ($31.50).
Several analysts have issued reports on HIK shares. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a report on Friday, September 23rd. Barclays PLC reissued an “overweight” rating and set a GBX 2,900 ($35.89) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Friday, September 9th. Numis Securities Ltd reissued a “hold” rating and set a GBX 2,660 ($32.92) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 24th. Jefferies Group reduced their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,990 ($37.00) to GBX 2,500 ($30.94) and set a “buy” rating on the stock in a research note on Monday, September 12th. Finally, Citigroup Inc. downgraded shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($32.18) price objective on the stock. in a research note on Thursday, August 4th.
In other Hikma Pharmaceuticals Plc news, insider Al-Husry,Ali acquired 140,000 shares of the company’s stock in a transaction dated Wednesday, August 31st. The stock was bought at an average price of GBX 2,150 ($26.61) per share, with a total value of £3,010,000 ($3,725,247.52). Also, insider Said Darwazah acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was acquired at an average cost of GBX 2,085 ($25.80) per share, with a total value of £208,500 ($258,044.55).
Hikma Pharmaceuticals Plc (LON:HIK) opened at 2018.08 on Thursday. The firm has a 50 day moving average of GBX 2,124.31 and a 200 day moving average of GBX 2,259.06. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,575.00 and a 1-year high of GBX 2,703.00. The firm’s market cap is GBX 4.56 billion.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.